We are a clinical-stage biotechnology company focused on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. Our leading product candidate, vebreltinib, has shown initial promising clinical results, and our strategic focus is the development of novel therapies targeting difficult to treat cancers using targeted, immuno-oncology, and other innovative approaches.
Status note Filing identifies vebreltinib as the most advanced / lead product candidate and notes the company has obtained orphan drug designation for it. Phase, indication, target, and modality not stated in the filing excerpts.
Per-asset detail extracted from the 20-F filed 2026-04-24. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.